Span Health is a digital care platform that aims to help people avoid lifestyle-induced diseases, symptoms, medication, and complications. The company has helped more than 10,000 people to live a better and longer life. Span Health's easy-to-use mobile application allows patients to chat with clinicians, order blood tests at home, book video consultations, and see results in the application itself. Moreover, in 2019, the company agreed on a National Health Service (NHS) pilot test for 100 patients in collaboration with the National Institute of Health Research in North West London. Span Health will use the investment to provide employees with blood tests to screen for health risk factors and recover from detected illness safely and sustainably, improve its platform data insights, prediction and machine learning to better structure the clinician's processes, and further reduce its operational costs.
days to go:
Expired
investment:
£134,892
Carocell Bio is an early-stage Research and Design (R&D) company aiming to develop nanoparticle-based, novel peptide anti-inflammatories to treat atopic dermatitis/eczema (AD) and other serious inflammatory diseases. It argues that millions of people continue to be affected by debilitating skin ailments, which in turn, escalates the development of new pharmaceutical drugs. The company asserts that the anti-inflammatory therapeutics market will reach US$122.6 billion by 2025 from US$95.9 billion in 2019. The company aims to be a major contender in this market. Carocell Bio has also been awarded an Innovate UK grant of £390,874. The company is seeking £1 million in equity investment over the next 12 months to show that their compounds work in human tissue biopsies of several inflammatory diseases.
days to go:
Expired
investment:
Withheld
Sol-Gel Materials and Application (SGMA) is a sustainable technology company that is using its new sol-gels to create sustainable solutions to plastic environmental waste. The company has researched and developed a non-plastic, non-toxic coating for products, from food packaging to electronics, that is water and oil resistant yet recyclable. Its product is the world’s only biodegradable, compostable, and recyclable (BCR) solution. The company's founder and CEO, Dr Fanya Ismail, has won the award 'Women in Innovation 2019' by Innovate UK and the company's work has been covered by BBC South East Today. The company plans to function as an IP management company, sub-contract manufacturing to chemical firms moving from bulk to advanced materials, and outsource distribution to partners, whose packaging customers serve brand owners.
days to go:
Expired
investment:
£611,040
Clooper is a property management platform. The company argues that 86% of private landlords in the UK manage their properties themselves, with many finding it time-consuming and stressful. Clooper seeks to solve this problem with a property management platform that connects landlords, tenants, trade services, and homeowners to facilitate easy transactions between them. It aims to be a significant contender in the £11 billion property management platform. The company points out that Paul Rothwell of Empire, a large residential landlord in England, has pledged £200,000 of investment to the company. Clooper aims to make move-ins quicker, repairs faster, and payments easier in the wake of Covid-19 which is fuelling the adoption of online services in the UK. The company will use the investment to hire key recruits, operationalise mobile apps, boost marketing, and enhance sales and operations.
days to go:
Expired
investment:
£409,847
Polysolar specialises in manufacturing photovoltaic windows capable of generating electricity, which can be used in buildings to generate clean renewable energy whilst also meeting planning regulations. Its technology is already in-use by major organisations such as Network Rail and Sainsbury's.
days to go:
Expired
investment:
£1,311,180
Exchange Train (ET) is an online comparison website where property solicitors have 24 hours to bid for the home-movers custom in real-time. ET argues that there are over 19,000 property solicitors in the UK each providing a different quality of service, price, and turnaround time. ET aims to overhaul this process. Its portal locates the top solicitors for the customer’s specific transaction, based not only on price but what's most important to the customer. ET has had over 10,000 visitors, generated over 650 quotes, and signed up 22 solicitors on its portal, to date. The company has also featured in TodaysConveyancer, The Property Industry Eye, and The Negotiator Magazine. It will use 30% of the investment towards accelerating website development, 36% towards boosting Public Relations (PR), 18% towards enhancing Google Ads and social media, and 16% towards growing business operations.
days to go:
Expired
investment:
£123,900
Quin is a mobile medical app that combines daily life experience with data from diabetes devices and phones and helps people decide how much insulin to take and when. They are on a mission to help people with insulin-treated diabetes make the best possible decisions through their app. The company have received a UK research and innovation grant. Apple has granted them insider access to their engineers and executives who are helping to get Quin to market, their app has a class I CE Mark, with two patents pending. With the investment, they will hire a product designer to enhance the user experience, achieve certification and compliance with new European Medical Device Regulations, develope B2B2C distribution partnerships and launch the Quin app in the UK and Europe in late 2020.
days to go:
Expired
investment:
£691,497
Brickowner aims to become the leading service provider for property developers and asset managers, ensuring benefits for both parties. The company asserts that it undertakes background checks of investors on its portal for the benefit of asset managers. It also ensures that investors can easily navigate its portal and find deals that suit their financial appetite. Brickowner successfully exited five investment rounds despite two investments happening in the wake of COVID-19. The platform has over 3,000 investors registered with over 700 active investors. It has overseen over £15 million worth of investments on its portal till date. Brickowner will use the investment towards technology up-gradation, develop its B2B capacity, and increase marketing initiatives to support company growth
days to go:
Expired
investment:
£290,362
Flooring Hut is a UK-based technology company that aims to disrupt the UK flooring industry valued at £2bn in 2017. Touted as the smarter way to buy new carpets & flooring, Flooring Hut has made 24,000+ online sales across domestic and trade sectors by building a huge network of independent installers. The company's USP is to connect a disjointed market and allow customers access to value products, samples, leading brands and a suitable, vetted local installer to perform the work. The key to its success to date has been a consistent and reliable mix of pricing, availability, and selection. Till date, the company has 786 registered trade customers, 140+ Flooring Hut Installer Network of members, and 12,000 products available for sale. With the proceeds, the company will develop its self-service platform functionality for customers and expand its reach on social media and affiliate marketing.
days to go:
Expired
investment:
£57,077
Luas Diagnostics (LD) aims to develop and market easy-to-use, rapid and accurate diagnostics tests with the aim of deploying these tests in remote settings away from centralised testing laboratories. The company has signed an exclusive distribution agreement with Chembio Diagnostics Systems (CDS) in the USA to market its Covid-19 antibody and antigen tests in the UK and Ireland. It has also signed a Memorandum of Understanding (MoU) with the University of Birmingham to develop saliva-based, rapid Covid-19 tests. LD is also working on coming up with a therapeutic drug monitoring system based on the same technology used worldwide to test people with diabetes for glucose levels in the blood. The company is developing the system so that it can be used at home, in pharmacies or GP surgery. The first product will test for Theophylline which is used to treat Chronic Obstructive Pulmonary Disease (COPD). LD will use the investment to grow its business across different verticals.
days to go:
Expired
investment:
£326,190
